

Product datasheet

Anti-C3d antibody [7C10] ab17453

★★★★★ [2 Abreviews](#) [11 References](#) [2 Images](#)

Overview

Product name	Anti-C3d antibody [7C10]
Description	Mouse monoclonal [7C10] to C3d
Host species	Mouse
Specificity	This product is specific to C3d, but also C3b and iC3b, since C3d is a product from C3b.
Tested applications	Suitable for: IHC
Species reactivity	Reacts with: Human
Immunogen	Full length native protein (purified) corresponding to Human C3d.
Epitope	Epitope specificity differs from that of ab17455 .
Positive control	IHC-P: Human kidney tissue.
General notes	<p>The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.</p> <p>If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As</p>

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage buffer	pH: 7.40 Preservative: 0.098% Sodium azide Constituents: PBS, 2.9% Sodium chloride
Purity	Protein A purified
Clonality	Monoclonal
Clone number	7C10
Myeloma	x63-Ag8.653
Isotype	IgG1

Light chain type

kappa

Applications

The Abpromise guarantee Our **Abpromise guarantee** covers the use of ab17453 in the following tested applications. The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
IF		1/10.
IHC		1/10.

Target

Function

C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

Tissue specificity

Plasma.

Involvement in disease

Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.

Sequence similarities

Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain.

Post-translational modifications


C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other

fragments such as C3d or C3g.
Phosphorylation sites are present in the extracellular medium.

Cellular localization


Secreted.

Images



Immunohistochemical analysis of human kidney labelling C3d with ab17453 at a dilution of 1/10. Plasma of veins were stained strongly.

Immunohistochemistry - Anti-C3d antibody [7C10]
(ab17453)



Immunofluorescent analysis of human kidney labelling C3d with ab17453 at a dilution of 1/10. Plasma of veins were stained strongly.

Immunofluorescence - Anti-C3d antibody [7C10]
(ab17453)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours

- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors